Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 6;12(1):152.
doi: 10.1186/s13023-017-0705-2.

Prevalence of Amyloidosis in Korea

Su Ra Seo  1   2 , Shin Yi Jang  3 , Ga Yeon Lee  4 , Bareun Choi  5 , Heeran Chun  6 , Eun Jeong Cho  7 , Sung-Il Cho  1
Affiliations

Prevalence of Amyloidosis in Korea

Su Ra Seo et al. Orphanet J Rare Dis. .

Abstract

Background: The aim of this study was to assess in amyloidosis prevalence in Korea between 2006 and 2015.

Methods: Primary diagnoses related to amyloidosis, regardless of subtype, were collected from the Korean National Health Insurance Service from 2006 through 2015.

Results: Overall, the age-standardized prevalence of amyloidosis was 0.93 (95% confidence interval (CI) 0.81, 1.04) persons per 100,000 persons in 2006 and 1.91 (95% CI 1.78, 2.05) persons per 100,000 persons in 2015. This included an increase from 0.43 (95% CI 0.35, 0.51) to 1.04 (95% CI 0.94, 1.14) persons per 100,000 persons in men and from 0.49 (95% CI 0.40, 0.57) to 0.87 (95% CI 0.77, 0.96) persons per 100,000 persons in women. In particular, the age-standardized prevalence of amyloidosis showed a greater increase in patients aged 65 years or older and in patients aged 45-64 years than in patients aged 20-44 years, for both men and women.

Conclusions: The overall age-standardized prevalence of amyloidosis was approximately 2 persons per 100,000 persons in 2015. The overall age-standardized prevalence of amyloidosis increased between 2006 and 2015, especially in individuals aged 45-64 and older than 65 years.

Keywords: Amyloidosis; Korea; Prevalence.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Evaluation of the study protocol was exempted by the Institutional Review Board of Samsung Medical Center (IRB No. 2017-02-032).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–2654. doi: 10.1016/S0140-6736(15)01274-X. - DOI - PubMed
    1. Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223–241. doi: 10.1146/annurev.med.57.121304.131243. - DOI - PubMed
    1. Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6:214–220. doi: 10.1016/j.coph.2005.10.005. - DOI - PubMed
    1. Merlini G. Systemic amyloidosis: are we moving ahead? Neth J Med. 2004;62:104–105. - PubMed
    1. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97:75–84. doi: 10.1136/hrt.2009.190405. - DOI - PubMed